Prostate cancer drug shows promise in triple-negative and estrogen-positive breast cancer

Long known to drive prostate cancer, androgen receptors are a new target in breast cancer treatment. This week, a promising clinical trial at the University of Colorado Cancer Center flips from Phase I (proving safety) to Phase II (proving effectiveness).

Read the whole article on Science Daily

More from Science Daily